Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting

Biomaterials

Volumn 35, Issue 17, 2014, Pages 4835-4847

  Liu, Yayuan ^a   Ran, Rui ^a   Chen, Jiantao ^a   Kuang, Qifang ^a   Tang, Jie ^a   Mei, Ling ^a   Zhang, Qianyu ^a   Gao, Huile ^a   Zhang, Zhirong ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

BBB penetrating; Cell penetrating peptide; Glioma targeting; Tandem peptide

Indexed keywords

CELL DEATH; DRUG DELIVERY; LIGANDS; LIPOSOMES; MAMMALS; PEPTIDES;

BBB PENETRATING; BLOOD-BRAIN BARRIER; CELL-PENETRATING PEPTIDE; DRUG DELIVERY SYSTEM; EFFICIENT TREATMENT; GLIOMA SPHEROIDS; GLIOMA TARGETING; SYSTEMIC ADMINISTRATION;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; CELL PENETRATING PEPTIDE; LIPOSOME; PACLITAXEL; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SPHEROID; ZETA POTENTIAL;

BBB PENETRATING; CELL PENETRATING PEPTIDE; GLIOMA TARGETING; TANDEM PEPTIDE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PACLITAXEL;

EID: 84896493907     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.031     Document Type: Article

References (59)

1. Deeken J.F., Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13:1663-1674.
2. Serwer L.P., James C.D. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 2012, 64:590-597.
3. Gao H., Jiang X. Progress on the diagnosis and evaluation of brain tumors. Cancer Imaging 2013, 13(4):466-481.
4. Gao H., Pang Z., Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 2013, 30(10):2485-2498.
5. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology 2000, 2(1):45-59.
6. Zhan C., Wei X., Qian J., Feng L., Zhu J., Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel invitro and invivo. JControl Release 2012, 160(3):630-636.
7. Sarin H., Kanevsky A.S., Wu H., Sousa A.A., Wilson C.M., Aronova M.A., et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. JTransl Med 2009, 7(51):1-13.
8. Lamfers M.L., Idema S., Bosscher L., Heukelom S., Moeniralm S., van der Meulen-Muileman I.H., et al. Differential effects of combined Ad5-δ24RGD and radiation therapy in invitro versus invivo models of malignant glioma. Clin Cancer Res 2007, 13:7451-7458.
9. Jiang X., Xin H., Gu J., Xu X., Xia W., Chen S., et al. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 2013, 34:1739-1746.
10. Chen Y., Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2012, 64:640-665.
11. Gao H., Yang Z., Cao S., Xiong Y., Zhang S., Pang Z., et al. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 2014, 35(7):2374-2382.
12. Lu W., Xiong C., Zhang R., Shi L., Huang M., Zhang G., et al. Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. JControl Release 2012, 161:959-966.
13. Veiseh O., Sun C., Fang C., Bhattarai N., Gunn J., Kievit F., et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009, 69(15):6200-6207.
14. Chen H., Tang L., Qin Y., Yin Y., Tang J., Tang W., et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci 2010, 40:94-102.
15. Gao H., Yang Z., Zhang S., Cao S., Pang Z., Yang X., et al. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. JControl Release 2013, 172(3):921-928.
16. Gao H., Qian J., Cao S., Yang Z., Pang Z., Pan S., et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012, 33(20):5115-5123.
17. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
18. Gao H., Pan S., Yang Z., Cao S., Chen C., Jiang X., et al. Acascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 2011, 32(33):8669-8675.
19. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 2012, 17(15-16):850-860.
20. Mae M., Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006, 6:509-514.
21. Qin Y., Chen H., Yuan W., Kuai R., Zhang Q., Xie F., et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011, 419:85-95.
22. Qin Y., Chen H., Zhang Q., Wang X., Yuan W., Kuai R., et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011, 420:304-312.
23. Ren Y., Hauert S., Lo J.H., Bhatia S.N. Identification and characterization of receptor-specific peptides for siRNA delivery. ACS Nano 2012, 6(10):8620-8631.
24. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. Atumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002, 8(7):751-755.
25. Fang B., Jiang L., Zhang M., Ren F.Z. Anovel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively. Biochimie 2013, 95(2):251-257.
26. Chen J.X., Wang H.Y., Li C., Han K., Zhang X.Z., Zhuo R.X. Construction of surfactant-like tetra-tail amphiphilic peptide with RGD ligand for encapsulation of porphyrin for photodynamic therapy. Biomaterials 2011, 32:1678-1684.
27. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res 2010, 339:269-280.
28. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. JControl Release 2011, 153:141-148.
29. 5 integrins. Cancer Res 2005, 65(10):4353-4361.
30. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31:179-189.
31. Gao H., Xiong Y., Zhang S., Yang Z., Cao S., Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 2014, 10.1021/mp400751g.
32. Yan H., Wang L., Wang J., Weng X., Lei H., Wang X., et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 2012, 6(1):410-420.
33. Cheng Y., Morshed R.A., Auffinger B., Tobias A.L., Lesniak M.S. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 2013, http://dx.doi.org/10.1016/j.addr.2013.09.006.
34. 1 integrins during human melanoma cell invasion. Cancer Res 1993, 53:3411-3415.
35. 3 integrin turnover regulates focal adhesion behavior. JCell Biol 2001, 155:1319-1332.
36. 3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol 2013, 40:788-794.
37. Brown R.C., Morris A.P., O'Neil R.G. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007, 1130:17-30.
38. Simon M.J., Kang W.H., Gao S., Banta S., Morrison B. Increased delivery of TAT across an endothelial monolayer following ischemic injury. Neurosci Lett 2010, 486:1-4.
39. Svensen N., Walton J.G., Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol Sci 2012, 33(4):186-192.
40. Yin Y., Wu X., Yang Z., Zhao J., Wang X., Zhang Q., et al. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res 2013, 30:2050-2062.
41. Kawaguchi Y., Tanaka G., Nakase I., Imanishi M., Chiba J., Hatanaka Y., et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking. Bioorg Med Chem Lett 2013, 23:3738-3740.
42. Biswas S., Deshpande P.P., Perche F., Dodwadkar N.S., Sane S.D., Torchilin V.P. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 2013, 335:191-200.
43. Gong C., Li X., Xu L., Zhang Y.H. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 2012, 33:3456-3463.
44. Gao H., Yang Z., Zhang S., Cao S., Shen S., Pang Z., et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013, 3:2534.
45. Gao H., Yang Z., Zhang S., Pang Z., Jiang X. Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles. JDrug Target 2014, 10.3109/1061186X.2014.886038.
46. Nichols B. Caveosomes and endocytosis of lipid rafts. JCell Sci 2003, 116(23):4707-4714.
47. Du W., Fan Y., Zheng N., He B., Yuan L., Zhang H., et al. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013, 34:794-806.
48. Diaz R., Mayorga L., Stahl P. Invitro fusion of endosomes following receptor-mediated endocytosis. JBiol Chem 1988, 263(13):6093-6100.
49. Wender P.A., Galliher W.C., Goun E.A., Jones L.R., Pillow T.H. The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 2008, 60:452-472.
50. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. JBiol Chem 2001, 276(8):5836-5840.
51. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006, 4(2):61-70.
52. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2012, 64:353-365.
53. Gao H., Qian J., Yang Z., Pang Z., Xi Z., Cao S., et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 2012, 33(26):6264-6272.
54. Gao H., Yang Z., Zhang S., Pang Z., Liu Q., Jiang X. Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 2014, 10(2):858-867.
55. Sharma G., Modgil A., Layek B., Arora K., Sun C., Law B., et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain invivo: biodistribution and transfection. JControl Release 2013, 167:1-10.
56. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5(4):496-504.
57. Huang Y., Jiang Y., Wang H., Wang J., Shin M.C., Byun Y., et al. Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev 2013, 65:1299-1315.
58. Lee S.H., Castagner B., Leroux J.C. Is there a future for cell-penetrating peptides in oligonucleotide delivery?. Eur J Pharm Biopharm 2013, 85:5-11.
59. Bechara C., Sagan S. Cell-penetrating peptides: 20 years later, what do we stand?. FEBS Lett 2013, 587:1693-1702.